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Contributions on vascular neurology
-----------------------------------

Johanna Ruhnau from Alexander Dressel\`s group in Greifswald reported on the effects of cerebral ischemia on monocyte and granulocyte function in cell culture assays from stroke patients. Next, Gilla Lättig from the group of Christoph Harms, Berlin, gave a talk on neuroprotective effects by E2 factor mediated ORC-1 repression in an oxygen glucose deprivation cell culture model. Peter Ludewig from Tim Magnus\` group studied the role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) in experimental stroke. Lack of CEACAM-1 increased infarct size, blood brain barrier breakdown as well as edema formation, which was accompanied by impaired neurologic outcome measures in the middle cerebral artery occlusion (MCAO) model via effects on granulocytes and MMP-9. Tian Zhang from Andreas Meisel\`s laboratory in Berlin focused on the effects of late CD4^+^ T cell depletion on vascular remodeling and clinical outcome in a murine MCAO stroke model. Robert Brunkhorst (from Christian Förch\`s group, Frankfurt) talked about effects of the sphingosin-1 receptor modulator fingolimod in the later phase after experimental cerebral ischemia. Finally, Eva Göb from the group of Christoph Kleinschnitz in Würzburg focused on the role of NADPH oxidases (NOX) in models of focal cerebral ischemia. She reported on stroke outcome in mice conditionally deficient for NOX4 in endothelial or smooth muscle cells thereby extending the already published data on constitutive *Nox4*^−/−^ mice.

Neuroimmunology and oligodendroglial biology
--------------------------------------------

Felipe Ortega from Mainz gave a talk on Wnt signalling pathways controlling distinct lineage commitment of subependymal zone stem cells giving rise to either oligodendroglial or neuronal cells. Next, Vasileia-Ismini Alexaki from the group of Trian Chavakis, Dresden, reported on the role of the tyrosine kinase receptor TrkA and its ligand nerve growth factor as modulator of microglia-mediated inflammation. Eva Tolosa from Hamburg focused on regulatoy T cells (T~reg~) positive for the cell surface marker CD39. These T~reg~ may modulate the ATP/adenosine axis in autoimmune diseases such as multiple sclerosis (MS). Verena Schultz from the group of Andreas Junker in Göttingen gave a presentation on the role of the immunomodulatory surface molecule integrin associated protein (CD47) during remyelination. They studied the role of CD47 for processes of demyelination *in vivo* (cuprizone model) and cell culture models of myelination. Agnes Kovacs from the group of Ralf Linker, Erlangen, talked about the role of alternative renin angiotensin (Ang) system signalling pathways including Ang1-7 and Mas in experimental autoimmune encephalomyelitis (EAE). Next, Thomas Korn from Munich gave a presentation on the consequences of VLA-4 blockade on the function of different CD4^+^ positive T helper cell subsets in a mouse model of acute viral encephalitis. Kerstin Berer from Harmut Wekerle\`s lab in Munich investigated the gut microbiota as new trigger for CNS-specific autoimmunity. Tobias Lanz from Michael Platten\`s group in Heidelberg presented data on the key role of protein kinase Cβ pathways for blood brain barrier function in EAE. PKCβ inhibitors like enzastaurin may prove to be promising compounds for the treatment of neuroinflammation. Focusing on CD8^+^ positive T cell antigen recognition, Eva Reuter from the group of Volker Siffrin (Mainz) provided data on *in vivo* imaging of cross recognition between OVA and MOG in CD8 T cells during EAE.

Bettina Trinschek from the Jonuleit laboratory in Mainz talked about the role of IL-6 in the regulation of T~reg~ function in humanized mice and MS patients. The „early" presence of IL-6 may induce resistance of effector T cells towards T~reg~. At the end of the session, Benjamin Schattling from Manuel Friese\`s group in Hamburg presented work on the role of transient receptor potential (TRP) ion channels in neuroinflammation. He focused on transient receptor potential melastatin (TRPM) 4 cation channels in neurodegeneration during EAE and TRPM2 in the MCAO model of cerebral ischemia.

Neuroscience and neurodegeneration
----------------------------------

Petra Hühnchen from the group of Wolfgang Böhmerle, Berlin, reported on the behavioral, electrophysiological and morphometric characterization of animal models of neuropathic pain induced with different chemotherapeutics with a focus on allodynia. Janos Groh from Rudolf Martini´s group in Würzburg gave a talk on neurodegeneration and the role of immune cells in the visual system of mouse models for infantile and juvenile neuronal ceroid lipofuscinosis. Focusing on peripheral innate immunity in Parkinon\`s disease (PD), Veselin Grozdanov from Karin Danzer\`s group in Ulm reported on cytokine profiles and function of isolated monocytes from PD patients. In a talk on sporadic proteopathies of the brain, Markus Krohn from Jens Pahnke\`s group in Magdeburg reported on the role of ABC transporters in Alzheimer\`s disease with a special focus on the effect of ABCB1 and ABCC1 regarding clearance mechanisms. Judith Alferink from the Department of Psychiatry in Münster investigated APP/PS1 mice and presented data on the role of CCL17 in neurodegeneration. CCL17 deficiency resulted in beneficial microglia responses and rescued mice from cognitive decline. Finally, Nadine Haase from Dominik Müller\`s group in Berlin provided a study on alpha1 adrenergic receptor (α1AR) and β-amyloid. Amyloid β peptides may activate α1AR thus providing a possible link between hypertension and Alzheimer\`s disease.
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